Evaluating collaborative care for postpartum depression in pediatric primary care settings (EPDS) trial

Evaluating collaborative care for Postpartum Depression in pediatric primary care Settings (EPDS) trial: a multi-centre randomised controlled trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN56529202

Enrollment

360

Registered

2014-10-02

Start date

2015-01-05

Completion date

Unknown

Last updated

2015-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum depression Mental and Behavioural Disorders Mild mental and behavioural disorders associated with the puerperium, not elsewhere classified

Interventions

Mothers randomly assigned to the treatment group will have access to usual postpartum care in addition to the treatment provided by the study, which will include the four standard criteria for collabo

(2) a structured management plan

(3) scheduled participant follow-ups

and (4) enhanced inter-professional communication.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Mothers who meet the following criteria: 1. Has a healthy child participating in the TARGet Kids! study 2. Is between 0 to 6 months postpartum 3. Edinburgh Postnatal Depression Scale (EPDS) score >9 at TARGet Kids! baseline and trial recruitment (2-stage assessment) 4. Understands spoken English

Exclusion criteria

Exclusion criteria: 1. Current use of antidepressant medication 2. Current receipt of any form of psychotherapy administered by a trained professional 3. Active suicidal or self-harm thoughts

Design outcomes

Primary

Measure	Time frame
Depressive symptoms as identified by the EPDS and Structured Clinical Interview for DSM-V (SCID-V) at 6 months post-randomization (immediately post-treatment)	—

Secondary

Measure	Time frame
What is the effect of the collaborative care treatment on: The mother?s 1. Depressive symptoms at 9 and 12 months post-randomization? 2. Anxiety at 6, 9, and 12 months post-randomization? 3. Quality of life at 6, 9, and 12 months post-randomization? 4. Health service use at 12 months randomization? The child?s 5. Cognitive development at 24 months of age? 6. Temperament at 12 and 24 months of age? 7. Language development at 18 months of age? Other questions: 1. What is the nature and intensity of the collaborative care treatment activities? 2. What are mothers? evaluations of their collaborative care experience? 3. Cost implications?	—

Measure

Time frame

What is the effect of the collaborative care treatment on: The mother?s 1. Depressive symptoms at 9 and 12 months post-randomization? 2. Anxiety at 6, 9, and 12 months post-randomization? 3. Quality of life at 6, 9, and 12 months post-randomization? 4. Health service use at 12 months randomization? The child?s 5. Cognitive development at 24 months of age? 6. Temperament at 12 and 24 months of age? 7. Language development at 18 months of age? Other questions: 1. What is the nature and intensity of the collaborative care treatment activities? 2. What are mothers? evaluations of their collaborative care experience? 3. Cost implications?

—

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026